Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Tharimmune ( (THAR) ) is now available.
On February 5, 2026, Tharimmune’s board elected Chief Executive Officer Mark Wendland as chairman, succeeding Vincent LoPriore, who remains on the board, and appointed former DRW and Citadel executive Angela Radkowski as chief operating officer to oversee operational controls and execution of the company’s Canton Network-focused initiatives, including its quarterly research program and Super Validator activation. The company also reported that it regained compliance with Nasdaq’s board independence requirements on February 2, 2026, after electing two independent directors at a January 30, 2026 shareholder meeting, reinforcing its governance structure as it pursues a differentiated digital asset treasury strategy centered on Canton Coin, institutional blockchain adoption, and investments in Canton Network applications alongside its ongoing biotech R&D activities.
More about Tharimmune
Tharimmune, Inc. (NASDAQ: THAR) is a hybrid digital-asset and biotech company, positioning itself as the first publicly traded business to leverage Canton Coin and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets, while also operating clinical-stage biotech research and development programs.
Average Trading Volume: 899,055
Technical Sentiment Signal: Buy
Current Market Cap: $187M
For detailed information about THAR stock, go to TipRanks’ Stock Analysis page.